News | ECG Monitoring Services | September 10, 2015

AliveCor Mobile ECG Shows Momentum as Tool for AFib Detection

AliveCor reports 30 percent of users have received an AFib detection that may otherwise have gone undiagnosed

AliveCor Mobile ECG, AFib, detection, atrial fibrillation

AliveCor Mobile ECG image courtesy of AliveCor

September 10, 2015 — AliveCor Inc. announced significant milestones related to patients with atrial fibrillation (AFib) using the AliveCor Mobile ECG. Since receiving the first U.S. Food and Drug Administration (FDA) clearance for the AF Detector, an algorithm to detect atrial fibrillation in an ECG (electrocardiogram), 30 percent of AliveCor patients have received an AFib detection. Additionally, more than 50 percent of U.S. users with an AFib detection received that detection within one week of their first AliveCor ECG recording, and close to 80 percent received it within one month.

September is AFib Awareness Month in the United States, which was started in 2009 by the Heart Rhythm Society in an effort to raise awareness of the increased prevalence of the disease and the associated risk of stroke in AFib patients. AFib is the most common cardiac arrhythmia and increases the risk of stroke up to five times. AFib can be hard to detect, as symptoms, including heart palpitations, may be mild or non-existent. The ability to automatically detect AFib using mobile technology like the AliveCor Mobile ECG has now proven to be an effective and important step in the detection of AFib so physicians can intervene before potentially life-threatening conditions, like strokes, occur.

"Atrial fibrillation is the most common arrhythmia in the United States. It can be challenging to detect, as almost 50 percent of patients are asymptomatic, until they develop a stroke or heart failure, which can be devastating. Being able to diagnose AFib before the development of complications has the potential to significantly improve the lives of numerous people," said Richard Wong, M.D., FACC, adult cardiologist, Kaiser Permanente Medical Group. "Having a mobile ECG monitoring device like the AliveCor Mobile ECG has been extremely helpful for me in my practice, specifically when screening for this potentially life-threatening arrhythmia."

An important step in AFib management is to understand a patient's lifestyle, daily activities and symptoms. The AliveECG app includes the Heart Journal, a feature that allows users to log daily activities, tag symptoms and events in real-time that can impact heart health and work to identify abnormalities. As this information is tracked alongside ECGs, both the patient and the treating physician have a more comprehensive picture of how the heart behaves under everyday conditions. Currently, 63 percent of U.S. users have tagged their ECGs in their Heart Journal.

"AliveCor's Heart Journal has been a helpful and easy way for me to learn about what is going on with my own heart by tracking my activities. Now, I do not have to try and remember what to tell my physician as I can easily share my notes and logs, and we can review the information together," said Linda Jankovic, an AliveCor user since June 2015.

AliveCor has seen tremendous growth throughout the past four years including expanded regulatory clearances, the launch of three algorithms, and adding almost 4 million AliveCor ECGs recorded into the AliveCor database. Additionally, the company has more than doubled the number of regular users and recordings in the last year and continues to expand globally, having entered nine new countries in 2015.

For more information:

Related Content

HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG| August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Clarius Wireless Ultrasound Scanners Now Available With Advanced Features
News | Ultrasound Imaging| August 09, 2017
Clarius Mobile Health has released advanced features and options for its wireless handheld ultrasound scanner for...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Overlay Init